As an oral veterinary product containing GS-441524, NeoFipronis® (Pronidesivir) is committed to providing a more convenient, transparent, and traceable oral GS-441524 product option for cats with FIP.
Vientiane, Laos — March 2, 2026 — NeoFipronis® (Pronidesivir) has been officially introduced as an oral GS-441524 veterinary product focused on feline infectious peritonitis (FIP).
NeoFipronis® (Pronidesivir) has been officially registered in Laos and is available through authorized channels. The product is designed to support a more standardized, traceable, and quality-controlled oral veterinary product option for FIP-related treatment management.
NeoFipronis® is the brand name of Pronidesivir. The product uses GS-441524 as its active ingredient and is formulated as oral tablets, aiming to meet the medication needs of cats with FIP during long-term treatment under veterinary guidance.
Feline infectious peritonitis is a serious disease associated with mutations of feline coronavirus. It may present with clinical signs such as abdominal effusion, pleural effusion, persistent fever, loss of appetite, weight loss, ocular symptoms, or neurological symptoms. Diagnosis and treatment of FIP require consideration of clinical signs, laboratory testing, imaging findings, and professional veterinary judgment.
The introduction of NeoFipronis® (Pronidesivir) focuses on addressing several key concerns commonly raised by cat owners regarding FIP-related products: whether the product source is legitimate, whether the ingredients are clearly defined, whether each batch is traceable, whether quality is controlled, and whether the medication is convenient for long-term administration.
NeoFipronis® will continue to improve its product trust system around “official registration, legitimate source, batch traceability, and quality control.” The website will provide product information, instructions for use, authorized-channel information, and verification support to help cat owners and veterinarians better understand the product.